Early Trading Has Precision (DTIL) Moving for June 22

Equities Staff  |

Precision Biosciences Inc (NASDAQ:DTIL) has already climbed $0.24 in early trading Wednesday.

After closing the previous trading session at $1.39, Precision has moved 17.27% higher ahead of market open.

The company has risen 14.88% over the last 5 days.

Today could shape up to be an interesting day for Precision investors.

For technical charts, analysis, and more on Precision Biosciences Inc visit the company profile.

Pre-market prices and movements as of 08:26:32 est.

About Precision Biosciences Inc

Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its wholly proprietary ARCUS® genome editing platform. ARCUS is a highly specific and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind. Using ARCUS, the Company's pipeline consists of multiple 'off-the-shelf' CAR T immunotherapy clinical candidates and several in vivo gene correction therapy candidates to cure genetic and infectious diseases where no adequate treatments exist.

To get more information on Precision Biosciences Inc and to follow the company's latest updates, you can visit the company's profile page here: Precision Biosciences Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?



Market Movers

Sponsored Financial Content